# Peptide API supplier checklist for pharmacies and manufacturers

> A peptide API supplier should provide the original manufacturer's identity and FDA establishment registration, evidence of cGMP manufacture under ICH Q7, a lot-specific certificate of analysis, a drug master file reference where one exists, audit access and a written change control commitment. Registration alone does not prove quality.

Source: https://internationalwholesalepeptides.com/guides/peptide-api-supplier-checklist/
Updated: 2026-11-18

Choosing a peptide API supplier is a regulated decision for a pharmacy or manufacturer. The buyer is responsible for the ingredients it uses. This checklist covers FDA establishment registration and its limits, drug master files, cGMP evidence, certificate requirements, supplier audits and change control. It is general information as of November 2026. Confirm requirements with your regulator or counsel.

## What a peptide API supplier must be able to show

| Area | Evidence to request | How to verify |
|---|---|---|
| Identity of the manufacturer | Legal name, site address, FEI or DUNS number | FDA registration database; company register |
| Establishment registration | Current registration for the manufacturing site | Search FDA's database by name |
| cGMP | Audit report, inspection history, GMP certificate, compliance statement | Read the reports; check dates and scope |
| Drug master file | DMF number and type; letter of authorization where needed | FDA's public DMF list |
| Certificate of analysis | Lot-specific, complete, signed | Compare with specification; confirm with the laboratory |
| Traceability | Chain of custody from manufacturer to you | Match lot numbers and dates across documents |
| Change control | Quality agreement clause | Read the notice period and scope |
| Stability | Data supporting the retest date | Review conditions and attributes tested |

## What FDA establishment registration proves and does not prove

Domestic and foreign establishments that manufacture, repack or relabel drugs for the US market must register with FDA and list their drugs under section 510 of the Federal Food, Drug, and Cosmetic Act and [21 CFR Part 207](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-207). Registration is submitted through FDA's [electronic drug registration and listing system](https://www.fda.gov/drugs/guidance-compliance-regulatory-information/electronic-drug-registration-and-listing-system-edrls) and renewed annually.

| Registration proves | Registration does not prove |
|---|---|
| The establishment has identified itself to FDA | That FDA has inspected the site |
| The site address and registered business operations | That the site complies with cGMP |
| That the registration is current, if listed | That any product is approved |
| A point of contact and, for foreign sites, a US agent | That a particular lot came from that site |

Part 207 states that registration or listing does not denote approval of the establishment or its products, and that representing otherwise is false. A supplier that presents a registration number as an FDA approval is making an inaccurate claim.

Verify registration yourself in the [Drug Establishments Current Registration Site](https://www.fda.gov/drugs/drug-approvals-and-databases/drug-establishments-current-registration-site-decrs). Check that the registered entity is the original manufacturer of the lot, not only a repackager or distributor. For compounding, the statutory conditions and the 2026 draft policy on six peptides both turn on the manufacturer; see [503A and 503B peptide sourcing](/guides/503a-503b-peptide-sourcing/).

## What a drug master file is

A [drug master file](https://www.fda.gov/drugs/forms-submission-requirements/drug-master-files-dmfs) is a confidential submission that gives FDA detailed information about facilities, processes or articles used in making a drug.

| Point | Detail |
|---|---|
| Type for APIs | Type II covers drug substances, intermediates and materials used in their preparation |
| Approval status | FDA does not approve or disapprove a DMF |
| When it is reviewed | Only when referenced by an application, through a letter of authorization |
| Public information | FDA publishes a list of DMFs with number, holder and status |
| What it signals | The manufacturer has documented its process in a regulatory format |
| What it does not signal | That FDA has found the process acceptable |

A DMF is not required for a substance to be used in compounding. Where one exists, it shows a level of documentation that supports qualification.

## What cGMP evidence looks like

cGMP for active ingredients rests on section 501(a)(2)(B) of the Act, and FDA's expectations follow [ICH Q7](https://database.ich.org/sites/default/files/Q7%20Guideline.pdf), published by FDA as [guidance for industry](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q7-good-manufacturing-practice-guidance-active-pharmaceutical-ingredients-guidance-industry). FDA lists the related rules on its [cGMP regulations](https://www.fda.gov/drugs/pharmaceutical-quality-resources/current-good-manufacturing-practice-cgmp-regulations) page.

| Evidence | Strength | Notes |
|---|---|---|
| Your own on-site audit | Strong | Scope and findings are yours to set |
| Qualified third-party audit report | Strong, if recent and in scope | Check the auditor's independence and the audit standard |
| Regulatory inspection history | Strong | Outcome and date matter; search FDA's public [warning letters](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters) |
| GMP certificate from a competent authority | Moderate to strong | Check the site, scope and expiry |
| Completed quality questionnaire | Moderate | Self-reported; verify samples of the answers |
| Signed cGMP compliance statement | Weak when it stands alone | Useful only alongside other evidence |

## What the certificate of analysis must contain

Section 11.4 of ICH Q7 describes certificates of analysis for APIs.

- Name of the API, grade where applicable, batch number and date of release.
- Expiry or retest date on the label and certificate.
- Each test performed, with acceptance limits and the numerical results obtained.
- Date and signature of authorized quality unit personnel.
- Name, address and telephone number of the original manufacturer.
- Where a repackager or reprocessor issues the certificate, its own name and address, with a reference to the original manufacturer and a copy of the original certificate attached.

For a synthetic peptide API, the test list normally includes the following.

| Test | Typical method |
|---|---|
| Appearance | Visual |
| Identity | Mass spectrometry; HPLC retention time against a reference standard; amino acid analysis |
| Purity and related substances | RP-HPLC, with individual and total impurity limits |
| Assay or peptide content | HPLC against a reference standard, amino acid analysis or nitrogen |
| Counter-ion | Ion chromatography or HPLC |
| Water | Karl Fischer |
| Residual solvents | Gas chromatography, against ICH Q3C limits |
| Bacterial endotoxins | USP <85> |
| Bioburden | Microbial enumeration |

Field-by-field guidance is in [how to read a peptide COA](/guides/how-to-read-a-peptide-coa/). Endotoxin methods are in [endotoxin and sterility testing](/guides/endotoxin-and-sterility-testing/).

## How to audit a peptide API supplier

| Audit area | What to look at |
|---|---|
| Quality unit | Independence, batch release authority, deviation and investigation records |
| Synthesis | Raw material qualification, in-process controls, defined critical steps |
| Purification | Column cleaning and reuse, fraction pooling criteria |
| Lyophilization | Cycle records, residual moisture results |
| Cross-contamination | Dedicated or cleaned equipment between products; cleaning validation |
| Laboratory | Method validation, reference standards, out-of-specification handling, data integrity |
| Stability | Ongoing program and results supporting the retest date |
| Records | Executed batch record for a lot you bought, traced from raw materials to shipment |
| Distribution | Storage, packaging qualification, temperature records |

If an on-site audit is not practical, use a remote audit or a qualified third-party auditor, and record why. Where you buy from a distributor, audit the distributor's traceability as well. Section 17 of ICH Q7 expects agents, traders and repackers to maintain traceability and pass information from the manufacturer to the customer.

## What change control should cover

A change that looks minor to the manufacturer can alter the impurity profile of a peptide. The quality agreement should require written notice before the following changes take effect.

| Change | Why it matters |
|---|---|
| Manufacturing site | New equipment, staff and environment |
| Synthesis route or scale | Different impurities; see [peptide synthesis explained](/guides/peptide-synthesis-explained/) |
| Raw material source | Amino acid derivative quality affects related substances |
| Purification or salt form | Changes counter-ion and content |
| Specification or analytical method | Results are no longer comparable |
| Testing laboratory | Method transfer needs verification |
| Container closure or storage condition | Affects stability |

Agree the notice period, the information the supplier will provide and your right to reject the change or requalify.

## A one-page qualification record

| Item | Complete |
|---|---|
| Manufacturer identified; registration verified by you | Yes or no |
| cGMP evidence reviewed and dated | Yes or no |
| DMF status recorded | Yes, no or not applicable |
| Lot-specific certificate reviewed against specification | Yes or no |
| First lot tested independently | Yes or no |
| Chain of custody documented | Yes or no |
| Quality agreement signed, with change notification | Yes or no |
| Audit completed or scheduled | Yes or no |
| Requalification date set | Yes or no |

## How International Wholesale Peptides supplies API buyers

We supply [bulk API powder](/formats/bulk-api-powder/) to licensed pharmacies and manufacturers after business verification. Every lot ships with a certificate of analysis that names the testing laboratory, and origin is stated per lot. Buyers can check a lot through the [lot lookup](/quality/lot-lookup/). The page for [compounding pharmacies](/for/compounding-pharmacies/) explains how to apply.

## Frequently asked questions

### Does FDA registration prove a peptide API supplier is compliant?

No. Registration under 21 CFR Part 207 is a required administrative listing of an establishment and its activities. FDA states that registration does not denote approval of the establishment or its products. It confirms that a site is known to FDA, not that it has passed an inspection.

### What is a drug master file for a peptide API?

A drug master file is a confidential submission to FDA with detailed chemistry, manufacturing and controls information. Type II files cover drug substances. FDA does not approve a drug master file. It reviews one only when an applicant references it in a drug application.

### What evidence shows cGMP manufacture?

Useful evidence includes a recent audit report by your own team or a qualified third party, the site's regulatory inspection history, a GMP certificate from a competent authority where one is issued, and a signed statement of compliance with ICH Q7. A statement alone is weak evidence.

### What must a certificate of analysis for a peptide API contain?

ICH Q7 expects the API name, batch number, release date, each test with its acceptance limit and numerical result, a dated signature from the quality unit, and the original manufacturer's name and address. Repackagers must show their own details and reference the original manufacturer.

### How often should an API supplier be audited?

Set the interval by risk. Many quality systems audit critical API suppliers before first use and then every two to three years, with earlier audits after a serious deviation, a regulatory action or a major change. Record the rationale for the interval you choose.

### What changes should an API supplier notify buyers about?

Changes to the manufacturing site, synthesis route, raw material sources, specification, analytical methods, container closure, storage condition and testing laboratory. The quality agreement should require notice before implementation, so the buyer can assess the effect on its own products.
